2017 EHA Annual Meeting Highlights


Successful Reduction in Treatment Intensity in Patients with Advanced-stage Hodgkin Lymphoma
Peter Borchmann, MD

Begin


Estimating the Efficacy of Novel Therapies in Classical Hodgkin Lymphoma
Paul Bröckelmann, MD

Begin


Evaluating the Efficacy of Nivolumab with and without Brentuximab Vedotin: New Trial Results and Treating Rare Lymphoma Cases: Effective Strategies for NHLPH
Andreas Engert, MD

Begin


The Clinical Impact of PET-guided Treatment in Advanced-stage Hodgkin Lymphoma
Andrea Gallamini, MD

Begin


Overall Survival in Classical Hodgkin Lymphoma: Real-world Experiences in Kentucky
Hayder Saeed, MD

Begin


Early Trial Results of Combination Therapy with Brentuximab Vedotin in Hodgkin Lymphoma are Very Promising
Anas Younes, MD

Begin

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved